event-image

Did you know that by the end of this year, its predicted breast cancer will be the most prevalent cancer in Australia?

Despite this heartbreaking statistic, to date there is little treatment that can combat breast cancer that has metastasised or spread to other areas of the body. Sadly, this is because many patients become resistant to current treatments over time.

Thanks to the incredible generosity of one of our very special donors, Dr Margaret Elcombe, our researchers have been awarded the Elcombe Pre-Clinical Project Grant to pursue a very promising new treatment avenue for breast cancer that has spread which if successful would be far less toxic than current treatments.

Dr Jenny Hardingham and Dr Amanda Townsend from the Basil Hetzel Institute for Translational Health Research (BHI) are part of a world-class research team working on this project, alongside Dr Yoko Tomita, Professor Andrea Yool, Associate Professor Wendy Ingman, Professor Tim Price and Professor Andreas Evdokiou.

“We’re excited by the possibility of a new therapy for metastatic breast cancer without the toxicity of current therapeutic drug treatments,” Dr Hardingham said.

“For someone with metastatic breast cancer there are a reasonable number of treatment options but eventually sadly patients become resistant to them,” Dr Townsend added.

Through previous research into bowel cancer, the team has discovered a particular protein that also plays a crucial role in the growth of breast cancer and the spread of cancer to other areas of the body.

“A protein called Aquaporin 1, a water channel protein, has been proved to play a vital role in assisting breast cancer cells to move to other areas of the body,” Dr Hardingham explained.

“This discovery provoked the suggestion that if we inhibit or block the action of this protein this may lead to a new cancer therapy.”

Thanks to the Margaret Elcombe Research Fellowship, Dr Townsend and Dr Hardingham are now exploring the effectiveness of two different inhibitors that could block the action of this protein and in turn stop breast cancer from growing and also spreading.

“It was found that if we blocked this particular protein it stopped angiogenesis, which is the formation of new blood vessels. New blood vessels are crucial for supplying the cancer tumour with the nutrients and oxygen it needs to survive, so without angiogenesis the tumour would not be able to grow,” Dr Hardingham said.

“This angiogenic process is also crucial for providing blood vessel access to enable cancer tumour cells to metastasise to distant sites such as lung or bone.

“These are the first inhibitors world-wide that target the Aquaporin 1 water channel that is so important for angiogenesis and metastasis.”

If Dr Townsend and Dr Hardingham and their expert team can prove these inhibitors to be successful in helping to limit the growth and spread of metastatic breast cancer, the next step for this research will be a clinical trial.

“We’re looking at a new treatment that will be far less toxic then current chemotherapy treatments and have far fewer side effects. If we’re successful in pre-clinical studies, the next step will be a clinical trial for a new therapy for metastatic breast cancer,” Dr Townsend said.

The support of the Margaret Elcombe Research Fellowship will allow Dr Townsend, Dr Hardingham and the team to continue this vital research for three years, in the hopes of improving outcomes and saving the lives of women diagnosed with metastatic breast cancer in the future.

you may also be interested in..

The Fight to Beat Triple Negative Breast Cancer

Head of the Cell Signalling Laboratory at the Centre for Cancer Biology (CCB), Associate Professor Yeesim Khew-Goodall is leading a crucial research project focused on overcoming resistance to cancer therapy, particularly in triple negative breast cancer. read more

Research Hope for Triple Negative Breast Cancer

Can you imagine being diagnosed with a type of cancer that has no targeted treatments? This could change thanks to researchers at the Basil Hetzel Institute for Translational Health Research (BHI) who are working hard to investigate possible treatments for triple negative breast cancer. read more

Adelaide’s Own Global Collaboration to Fight Cancer

Leading cutting-edge research into inflammation in a variety of cancers, Professor Vinay Tergaonkar from Singapore’s Agency for Science Technology and Research (A*Star) joined the Centre for Cancer Biology (CCB) in 2016, a unique new research laboratory collaboration. read more

PhD Finding to Potential Breast Cancer Treatment

In 2015 we introduced you to the incredible work of Dr Bill Panagopoulos, who was leading world-first research into an enzyme believed to play an essential role in the spread of breast cancer to the bone. Finishing his PhD last year, we’re excited to share with you the results of his research as he moves one step closer to a new treatment for secondary breast cancer. read more

Fighting Cancer with Your Own Immune System

Ground-breaking research is underway boosting the body’s own immune system to fight the most common cancers affecting Australian families, including breast cancer. The treatment is known as immunotherapy, and whilst it’s currently revolutionising blood cancer treatment, when it comes to solid cancers like breast cancer it’s not known to be as effective. read more

Cancer Research: It Will Save lives!

You can feel proud knowing you’re supporting research at all career levels, including the fresh young minds who are the future of medical research! PhD candidate Vahid Atashgaran’s exciting research has promising outcomes for the prevention of breast cancer in the future. read more